For instance, dual inhibition of VEGFR and Ang2 using cediranib (Recentin, AstraZeneca) in combination with an anti-Ang2-neutralizing antibody or simultaneous targeting of both pathways with a bispecific antibody resulted in an extended normalization window in orthotopic GBM models, leading to prolonged survival68,69 (Fig. 1b). This evidence concerns the gene KDR and glioblastoma.